Neutralizing Interferon Type 1 in Hidradenitis Suppurativa
ConditionHidradenitis Suppurativa (HS)
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire de Besancon
About this trial
The purpose of the study is to evaluate the safety and type 1 Interferon (IFN) neutralization in patients with refractory severe Hidradenitis Suppurativa (Hurley stage III) after transfusion of plasma containing high titer anti-IFN-1 autoantibodies.
Eligibility criteria
Qualifiers
Men and women aged over 18
Patients with Hidradenitis suppurativa (Hurley stages II-III)
Disease affecting at least two distinct anatomical areas,
Total count of abscesses (A) and inflammatory nodules (N) ≥ 3
Disqualifiers
Active viral infection: herpes, VZV, HIV, HBV, HCV
Active bacterial infection requiring systemic antibiotics
Known allergy to blood components/plasma proteins
Poor myocardial function (increased risk of for transfusion-associated circulatory overload) (symptomatic left ventricular failure and ejection fraction < 40%)
Trial design
Treatments tested in this trial
- Plasma with neutralizing autoantibodies to Type I Interferons
Treatment groups
6 Participants
are divided into 1 treatment groupSponsors and collaborators
Centre Hospitalier Universitaire de Besancon
Lead sponsor
Etablissement Français du Sang
Collaborator
Source ClinicalTrials.gov